University of Oxford
- Country
- 🇬🇧United Kingdom
- Ownership
- Private
- Established
- 1096-01-01
- Employees
- 10K
- Market Cap
- -
- Website
- http://www.ox.ac.uk
Stratified TreAtment to Reduce Risk in COPD
- First Posted Date
- 2020-07-07
- Last Posted Date
- 2020-07-21
- Lead Sponsor
- University of Oxford
- Target Recruit Count
- 203
- Registration Number
- NCT04458636
- Locations
- 🇬🇧
Nuffield Department of Medicine, Oxford, United Kingdom
COVID-19 Vaccine (ChAdOx1 nCoV-19) Trial in South African Adults With and Without HIV-infection
- First Posted Date
- 2020-06-23
- Last Posted Date
- 2020-11-27
- Lead Sponsor
- University of Oxford
- Target Recruit Count
- 2130
- Registration Number
- NCT04444674
- Locations
- 🇿🇦
Soweto Clinical Trials Centre, Johannesburg, Gauteng, South Africa
🇿🇦PHRU Kliptown, Johannesburg, Gauteng, South Africa
🇿🇦Setshaba Research Centre (SRC), Soshanguve, Gauteng, South Africa
Research Study to Assess New Chikungunya and Zika Vaccines in Healthy Adults in Mexico.
- First Posted Date
- 2020-06-22
- Last Posted Date
- 2022-03-23
- Lead Sponsor
- University of Oxford
- Target Recruit Count
- 120
- Registration Number
- NCT04440774
- Locations
- 🇲🇽
Hospital Universitario "Dr. José Eleuterio González" de la Universidad Autónoma de Nuevo León., Monterrey, Nuevo León, Mexico
Remote-by-Default Care in the COVID-19 Pandemic
- Conditions
- First Posted Date
- 2020-06-17
- Last Posted Date
- 2022-04-11
- Lead Sponsor
- University of Oxford
- Target Recruit Count
- 103
- Registration Number
- NCT04435041
- Locations
- 🇬🇧
University of Oxford, Oxford, United Kingdom
STerOids in COVID-19 Study
- First Posted Date
- 2020-06-04
- Last Posted Date
- 2021-02-08
- Lead Sponsor
- University of Oxford
- Target Recruit Count
- 146
- Registration Number
- NCT04416399
- Locations
- 🇬🇧
Oxford Respiratory Trials Unit, Oxford, Oxfordshire, United Kingdom
Investigating a Vaccine Against COVID-19
- Conditions
- Interventions
- Biological: ChAdOx1 nCoV-19 (qPCR)Biological: ChAdOx1 nCoV-19 (Abs 260)Biological: ChAdOx1 nCoV-19 0.5mL prime plus boostBiological: ChAdOx1 nCoV-19 (Abs 260) + 2.2x10^10vp (qPCR) boostBiological: Two dose ChAdOx1 nCoV-19/Covishield 0.25mL & 0.5mLBiological: Two dose ChAdOx1 nCoV-19/Covishield 0.5mLBiological: MenACWY vaccineBiological: Two dose MenACWY vaccine min. 4 weeks apartBiological: Two dose MenACWY vaccine
- First Posted Date
- 2020-05-26
- Last Posted Date
- 2023-08-01
- Lead Sponsor
- University of Oxford
- Target Recruit Count
- 12390
- Registration Number
- NCT04400838
- Locations
- 🇬🇧
University Hospital Southampton NHS Foundation Trust, Southampton, Hampshire, United Kingdom
🇬🇧University College London Hospitals NHS Foundation Trust, London, United Kingdom
🇬🇧John Radcliffe Hospital, Oxford, United Kingdom
The Effect of a Single Dose of Lamotrigine on Brain Function in Healthy Volunteers
- First Posted Date
- 2020-05-21
- Last Posted Date
- 2020-05-21
- Lead Sponsor
- University of Oxford
- Target Recruit Count
- 36
- Registration Number
- NCT04396938
- Locations
- 🇬🇧
University of Oxford, Oxford, Oxfordshire, United Kingdom
Neonatal Complications of Coronavirus Disease (COVID-19)
- Conditions
- Interventions
- First Posted Date
- 2020-05-13
- Last Posted Date
- 2020-05-13
- Lead Sponsor
- University of Oxford
- Target Recruit Count
- 500
- Registration Number
- NCT04386109
- Locations
- 🇬🇧
Imperial College, London, United Kingdom
A Multicentre Open-label Two-arm Randomised Superiority Clinical Trial of Azithromycin Versus Usual Care In Ambulatory COVID19 (ATOMIC2)
- First Posted Date
- 2020-05-11
- Last Posted Date
- 2021-05-06
- Lead Sponsor
- University of Oxford
- Target Recruit Count
- 298
- Registration Number
- NCT04381962
- Locations
- 🇬🇧
Horton General Hospital, Banbury, Oxfordshire, United Kingdom
🇬🇧John Radcliffe Hospital, Oxford, Oxfordshire, United Kingdom
🇬🇧Ninewells Hospital, Dundee, Scotland, United Kingdom
Randomised Evaluation of COVID-19 Therapy
- Conditions
- Interventions
- Drug: Lopinavir-RitonavirBiological: Convalescent plasmaBiological: ImmunoglobulinDrug: CorticosteroidDrug: Synthetic neutralising antibodiesDrug: EmpagliflozinDrug: AnakinraDrug: High Dose CorticosteroidDrug: SotrovimabDrug: PaxlovidDrug: Baloxavir MarboxilDrug: HydroxychloroquineDrug: AzithromycinDrug: TocilizumabDrug: AspirinDrug: Dimethyl fumarateDrug: ColchicineDrug: BaricitinibDrug: OseltamivirDrug: Molnupiravir
- First Posted Date
- 2020-05-11
- Last Posted Date
- 2024-01-05
- Lead Sponsor
- University of Oxford
- Target Recruit Count
- 70000
- Registration Number
- NCT04381936
- Locations
- 🇻🇳
Oxford University Clinical Research Unit, Centre for Tropical Medicine, Ho Chi Minh City, Vietnam
🇬🇭Kumasi Center for Collaborative Research in Tropical Medicine KNUST, Kumasi, Ghana
🇮🇳Indian Council of Medical Research, Division of Epidemiology and Communicable Diseases, New Delhi, India